CD117和神经巢蛋白在三阴性乳腺癌组织中的表达及临床意义  

Expression and clinical significance of CD117 and Nestin in triple negative breast carcinoma

作　　者：冯稳[1] 宋魏[1] 于庆凯[1] 赵冬梅[1] 

机构地区：[1]郑州大学附属肿瘤医院(河南省肿瘤医院)病理科,河南郑州450003

出　　处：《中国现代医学杂志》2016年第8期48-50,共3页China Journal of Modern Medicine

基　　金：河南省医学科技攻关计划项目(No:2011020159)

摘　　要：目的探讨CD117、神经巢蛋白(Nestin)在三阴性乳腺癌(TNBC)组织中的表达及临床意义。方法收集2010年11月-2012年5月于本院手术治疗的乳腺癌患者肿瘤组织病理切片,随机选取其中50例经免疫组织化学染色ER、PR、HER2均为阴性者,设为实验组。另随机选取普通乳腺癌组织50例,设为对照组。通过免疫组织化学方法研究正常实验组和对照组切片组织中CD117、Nestin的表达情况,分析CD117、Nestin在TNBC中的临床意义。结果实验组CD117、Nestin表达阳性率显著高于对照组,差异有统计学意义(P<0.05)。结论在TNBC组织中CD117、Nestin的表达显著上调,与TNBC的发生关系密切。Objective To investigate the expression and clinical significance of CD117、an nestin in triple negative breast carcinoma. Methods Pathological sections of tumor tissues from breast cancer patients were collected in our hospital between 2010 and 2012. Total 50 cases negative for ER、PR、HER2 were randomly selected as experimental group. Other 50 general breast cancer cases were randomly selected as control group. The expression of CD117 and Nestin was detected by immunohistochemistry. Results The expression of CD117 and Nestin in the experimental group was higher than that in the control group（P〈0.05）. Conclusions The expression of CD117 and Nestin is higher in the triple negative breast carcinomas, which is closely related to the occurrence of this disease.

关 键 词：CD117 NESTIN 免疫组织化学 三阴性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]